Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
UNLABELLED: Background Allogeneic hematopoietic cell transplantation is considered the preferred post-remission therapy in patients with acute myeloid leukemia cytogenetically defined as being at high risk. To substantiate evidence for allogeneic hematopoietic cell transplantation in first complete remission in these high-risk patients we performed a landmark analysis within a single prospective multicenter treatment trial. DESIGN AND METHODS: By the time of analysis, 2,347 patients had been accrued into the AMLCG 99 trial between 1999 - 2007. Out of this population, 243 patients under 60 years old fulfilled the criteria for high-risk cytogenetics. Landmark analyses were performed with a control cohort, who remained in first complete remission at least the median time from complete remission to transplantation in the intervention group. RESULTS: After standardized induction therapy, 111 patients under 60 years old achieved complete remission. A matched allogeneic donor was identified for 59 patients (30 sibling donors, 29 unrelated donors). Fifty-five patients received an allogeneic hematopoietic cell transplant after a median time of 88 days in first complete remission. Of the remaining 56 patients, 21 relapsed within 90 days after achieving first complete remission and for 7 patients with relevant comorbidities no donors search was initiated, leaving 28 patients given conventional post-remission therapy as the control cohort. The median follow-up of surviving patients was 60.4 months. Patients with an allogeneic donor had substantially better 5-year overall and relapse-free survival rates than the control group (48% versus 18%, P=0.004 and 39% versus 10%, P<0.001, respectively). A survival benefit from transplantation was evident regardless of donor type, age and monosomal karyotype. Conclusions Beyond evidence available for subgroups of high-risk patients, the findings of this study establish in a broader manner that allogeneic hematopoietic cell transplantation is a preferable consolidation treatment for patients with acute myeloid leukemia and high-risk cytogenetics. The study was registered at Clinicaltrials.gov as NCT00266136.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial
- Date Crossref
- 01/04/2011
- Éditeur
- Ferrata Storti Foundation (Haematologica)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Münster pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital Münster pays non établi dans la noticeÉtablissement de santé
-
Essen University Hospital pays non établi dans la noticeOrganisme public
-
Ludwig-Maximilians-Universität München pays non établi dans la noticeUniversité ou école supérieure
-
University of Regensburg Department of Hematology and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Deutsche Klinik für Diagnostik pays non établi dans la noticeÉtablissement de santé
-
Charité - Universitätsmedizin Berlin pays non établi dans la noticeÉtablissement de santé
-
University of Muenster Department of Medicine A/Hematology and Oncology pays non établi dans la noticeUniversité ou école supérieure
-
University Hospital of Essen Department of Bone Marrow Transplantation pays non établi dans la noticeUniversité ou école supérieure
-
University of Munich-Grosshadern Department of Internal Medicine III pays non établi dans la noticeUniversité ou école supérieure
-
Centre for Bone Marrow and Blood Stem Cell Transplantation pays non établi dans la noticeInstitution
-
Department of Hematology and Oncology pays non établi dans la noticeInstitution
University of Münster, University Hospital Münster et Essen University Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.